Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BY-NC-NDCancer medicine

Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database

  • Daniel J. George1
  • Jasmina I. Ivanova2
  • Maëlys Touya3
  • Betty Thompson2
  • Jonathan Assayag2
  • Benjamin Li2
  • Nikolaos Kountouris2
  • Gordon Siu2
  • Stephen J. Freedland4
4 affiliations
  1. 1Duke Cancer Institute
  2. 2Pfizer Inc.
  3. 3Astellas Pharma Inc.
  4. 4Cedars‐Sinai Medical Center
Read full textPDFCite

Related

  1. Real-World Early Prostate-Specific Antigen Response Comparison Among Patients with Metastatic Castration Sensitive Prostate Cancer Treated with Apalutamide or Abiraterone Acetate in the United States.
    Benjamin Lowentritt, Mehmet A Bilen, Sabree Burbage +6
    Journal of health economics and outcomes researchPeer-reviewedCC BYFull textOncologyEurope PMCPMC
  2. Cost-Utility Analysis of First-Line Olaparib plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer in China after Volume-Based Procurement
    J. SHI, Q. Gu, J. Pan +2
    medRxivPreprintCC BYFull textEpidemiology & public healthmedRxiv
  3. Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)
    Chi Kin Law, Martin R. Stockler, Andrew J. Martin +3
    EClinicalMedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref
  4. Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
    Apostolia M. Tsimberidou, Christopher R. Cabanski, Alexandra Drakaki +15
    Science advancesPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  5. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
    Matthew Smith, Howard Scher, Shahneen Sandhu +129
    Lancet OncologyPeer-reviewedCC BY-NC-ND175 citedOncologyHAL

Cite

BibTeXRIS
BibTeX
@article{george2026realworld,
  title = {{Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database}},
  author = {Daniel J. George and Jasmina I. Ivanova and Maëlys Touya and Betty Thompson and Jonathan Assayag and Benjamin Li and Nikolaos Kountouris and Gordon Siu and Stephen J. Freedland},
  journal = {Cancer medicine},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13658838},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database
AU  - Daniel J. George
AU  - Jasmina I. Ivanova
AU  - Maëlys Touya
AU  - Betty Thompson
AU  - Jonathan Assayag
AU  - Benjamin Li
AU  - Nikolaos Kountouris
AU  - Gordon Siu
AU  - Stephen J. Freedland
PY  - 2026
DA  - 2026/10/01
JO  - Cancer medicine
UR  - https://europepmc.org/article/PMC/PMC13658838
SN  - 2045-7634
ER  -